Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2011

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.

Philpott M, Yang J, Tumber T, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Keates T, Felletar I, Ciulli A, Knapp S, Heightman TD

Mol Biosyst. 2011-10-1 . 7(10):2899-908 .doi: 10.1039/c1mb05099k

PMID: 21804994

Kinase inhibitor selectivity profiling using differential scanning fluorimetry.

Fedorov O, Niesen FH, Knapp S

Methods Mol. Biol.. 2011-10-1 . 795:109-18 .doi: 10.1007/978-1-61779-337-0_7

PMID: 21960218

Bromodomains as therapeutic targets.

Muller S, Filippakopoulos P, Knapp S

Expert Rev Mol Med. 2011-9-22 . 13:e29 .doi: 10.1017/S1462399411001992

PMID: 21933453

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS

Chem. Biol.. 2011-7-29 . 18(7):868-79 .doi: 10.1016/j.chembiol.2011.05.010

PMID: 21802008

Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.

Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP

J. Med. Chem.. 2011-6-23 . 54(12):4172-86 .doi: 10.1021/jm200274d

PMID: 21615147

Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.

Feng L, Geisselbrecht Y, Blanck S, Wilbuer A, Atilla-Gokcumen GE, Filippakopoulos P, Kräling K, Celik MA, Harms K, Maksimoska J, Marmorstein R, Frenking G, Knapp S, Essen LO, Meggers E

J. Am. Chem. Soc.. 2011-4-20 . 133(15):5976-86 .doi: 10.1021/ja1112996

PMID: 21446733

DNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramer.

Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schäfer B, Hannewald J, Luh LM, Durst FG, Ibrahim M, Hoffmann J, Niesen FH, Sentürk A, Kunkel H, Brutschy B, Schleiff E, Knapp S, Acker-Palmer A, Grez M, McKeon F, Dötsch V

Cell. 2011-2-18 . 144(4):566-76 .doi: 10.1016/j.cell.2011.01.013

PMID: 21335238

Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.

Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S

Chem. Biol.. 2011-1-28 . 18(1):67-76 .doi: 10.1016/j.chembiol.2010.11.009

PMID: 21276940

Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase.

Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, Rönnstrand L, Knapp S, Bullock AN, Flores-Morales A

J. Biol. Chem.. 2011-1-7 . 286(1):480-90 .doi: 10.1074/jbc.M110.173526

PMID: 21030588